Research progresses of the PARP inhibitors for the treatment of cancer.
- Author:
Yujun HE
;
Ruihuan LIU
;
Chengqing NING
;
Niefang YU
- Publication Type:Journal Article
- From:
Acta Pharmaceutica Sinica
2013;48(5):655-60
- CountryChina
- Language:Chinese
-
Abstract:
The poly(ADP-ribose) polymerases (PARPs) is an important group of enzymes in DNA repair pathways, especially the base excision repair (BER) for DNA single-strand breaks (SSBs) repair. Inhibition of PARP in DNA repair-defective tumors (like those with BRAC1/2 mutations) can lead to cell death and genomic instability, what is so called "synthetic lethality". Currently, PARP inhibitors combined with cytotoxic chemotherapeutic agents in the treatment of BRCA-1/2 deficient cancers are in the clinical development. In this review, we will be focused on the development of combination application of PARP inhibitors with other anticancer agents in clinical trials.
